Melanoma Clinical Trial

Clinical Trial Finder Melanoma Trials

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing’s Disease

See Locations Near You

Summary

This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.

View Eligibility Criteria

Eligibility Criteria

Inclusion criteria

18 years or greater
Confirmed diagnosis of ACTH-dependent Cushing's disease
Not considered candidate for pituitary surgery

Exclusion criteria

History of pituitary irradiation in the last 10 years
Cushing's syndrome not caused by pituitary tumor
Patients with active malignant disease (cancer) in the last 5 years
Women who are pregnant or lactating

Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

162

Study ID:

NCT00434148

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 66 Locations for this study

See Locations Near You

Stanford University Medical Center Stanford Cancer Center (3)
Stanford California, 94304, United States
University Chicago Hospital Dept. of Univ of Chicago
Chicago Illinois, 60637, United States
Dana Farber Cancer Institute The Melanoma Program
Boston Massachusetts, 02115, United States
Columbia University Medical Center- New York Presbyterian Columbia University DeptofMed
New York New York, 10032, United States
Cleveland Clinic Foundation Dept. of Cleveland Clinic (6)
Cleveland Ohio, 44195, United States
Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU.
Portland Oregon, 97239, United States
University of Texas Southwestern Medical Center Clinical-TranslationalRes.Ctr.
Dallas Texas, 75390, United States
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(8)
Houston Texas, 77030, United States
Baylor College of Medicine
Houston Texas, 77030, United States
Swedish Medical Center Dept.ofSeattle Neuroscience(2)
Seattle Washington, , United States
Novartis Investigative Site
Capital Federal Buenos Aires, 1425E, Argentina
Novartis Investigative Site
Buenos Aires , C1232, Argentina
Novartis Investigative Site
Buenos Aires , C1405, Argentina
Novartis Investigative Site
Edegem , 2650, Belgium
Novartis Investigative Site
Gent , 9000, Belgium
Novartis Investigative Site
Curitiba PR, 80060, Brazil
Novartis Investigative Site
Rio de Janeiro RJ, 21941, Brazil
Novartis Investigative Site
Porto Alegre RS, 90560, Brazil
Novartis Investigative Site
Ribeirao Preto SP, 14048, Brazil
Novartis Investigative Site
Sao Paulo SP, 05403, Brazil
Novartis Investigative Site
São Paulo SP, 01401, Brazil
Novartis Investigative Site
Edmonton Alberta, T6G 2, Canada
Novartis Investigative Site
Halifax Nova Scotia, B3H 2, Canada
Novartis Investigative Site
Montreal Quebec, H2W 1, Canada
Novartis Investigative Site
Beijing Beijing, 10073, China
Novartis Investigative Site
Beijing , 10002, China
Novartis Investigative Site
Shanghai , 20002, China
Novartis Investigative Site
Arhus , 8000, Denmark
Novartis Investigative Site
Copenhagen , DK-21, Denmark
Novartis Investigative Site
Herlev , DK-27, Denmark
Novartis Investigative Site
Helsinki , FIN-0, Finland
Novartis Investigative Site
Angers , 49033, France
Novartis Investigative Site
Grenoble Cédex 9 , 38043, France
Novartis Investigative Site
LILLE Cedex , 59037, France
Novartis Investigative Site
Limoges cedex , 87042, France
Novartis Investigative Site
Marseille cedex 05 , 13385, France
Novartis Investigative Site
Paris , 75014, France
Novartis Investigative Site
Pessac Cedex , 33604, France
Novartis Investigative Site
St Priest en Jarez Cedex , 42277, France
Novartis Investigative Site
Toulouse Cedex 9 , 31000, France
Novartis Investigative Site
Berlin , 10098, Germany
Novartis Investigative Site
Essen , 45122, Germany
Novartis Investigative Site
Muenchen , 80336, Germany
Novartis Investigative Site
Würzburg , 97080, Germany
Novartis Investigative Site
Athens GR, 105 5, Greece
Novartis Investigative Site
Athens GR, 115 2, Greece
Novartis Investigative Site
Haifa , 33394, Israel
Novartis Investigative Site
Heifa , 35152, Israel
Novartis Investigative Site
Jerusalem , 91120, Israel
Novartis Investigative Site
Petach Tikva , 49100, Israel
Novartis Investigative Site
Ancona AN, 60126, Italy
Novartis Investigative Site
Cona FE, 44100, Italy
Novartis Investigative Site
Milano MI, 20149, Italy
Novartis Investigative Site
Milano MI, 20162, Italy
Novartis Investigative Site
Padova PD, 35128, Italy
Novartis Investigative Site
Pisa PI, 56124, Italy
Novartis Investigative Site
Orbassano TO, 10043, Italy
Novartis Investigative Site
Torino TO, 10126, Italy
Novartis Investigative Site
Napoli , 80131, Italy
Novartis Investigative Site
México Distrito Federal, 06720, Mexico
Novartis Investigative Site
México Distrito Federal, 14269, Mexico
Novartis Investigative Site
Warszawa , 01 80, Poland
Novartis Investigative Site
Porto , 4200-, Portugal
Novartis Investigative Site
Sevilla Andalucia, 41013, Spain
Novartis Investigative Site
Barcelona , 08041, Spain
Novartis Investigative Site
Ankara , 06100, Turkey
Novartis Investigative Site
Balcova / Izmir , 35340, Turkey
Novartis Investigative Site
Fatih / Istanbul , 34098, Turkey
Load More

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

162

Study ID:

NCT00434148

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider